相关实验视频

Updated: Mar 3, 2026

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

肠道微生物群的组成是由多发性硬化症患者的疾病活性和个体治疗反应塑造的

Veronika Ticha¹, Stepan Coufal², Zuzana Jiraskova Zakostelska²

¹Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.

Frontiers in immunology

|March 2, 2026

概括

多发性硬化症 (MS) 的肠道微生物群在患有活跃疾病和治疗不响应患者中存在差异. 这些差异表明肠道屏障受损,导致MS中微生物转移和炎症增加.

科学领域:

神经免疫学神经免疫学
微生物组研究微生物组研究
胃肠病学胃肠病学

背景情况:

多发性硬化症 (MS) 是一种慢性自身免疫性中枢神经系统疾病.
肠道微生物群在多发性硬化症的发病过程中发挥着关键作用.
了解微生物群在治疗反应中的作用至关重要.

研究的目的:

研究MS患者的肠道微生物群组成.
分析基于治疗状态和反应的微生物群差异.
评估与肠道微生物群和疾病活性相关的微生物转移生物标志物.

主要方法:

横截面研究设计. 截面研究设计.
用于肠道微生物群分析的16S rRNA测序.
血清生物标志物分析 (LPS结合蛋白,曼诺斯结合莱克).

主要成果:

与健康对照组 (HC) 相比,临床隔离综合征 (CIS) 和非响应者 (NR) 呈现出改变的α和β多样性.
克拉迪治疗改变了多样性,无论结果如何.
CIS和NR患者在短链脂肪酸生产细菌中表现出差异.
在CIS和NR中增加的LPS结合蛋白和曼诺斯结合莱克表明肠道屏障功能受损和微生物转移.

结论:

治疗显著影响MS的肠道微生物群组成.
患有活跃多发性硬化症 (CIS,NR) 的患者具有相似的肠道微生物群概况.
肠道屏障功能受损和微生物转移与活跃的MS有关,可能会促进炎症.

关键词:

克拉德里宾 (cladribine) 是一种药物.改变疾病的疗法.这就是fingolimod的意思.干扰子-β的干扰.多发性硬化症多发性硬化症神经炎症是一种神经炎症.血清中的生物标志物

更多相关视频

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Investigation of Microbial Cooperation via Imaging Mass Spectrometry Analysis of Bacterial Colonies Grown on Agar and in Tissue During Infection

Investigation of Microbial Cooperation via Imaging Mass Spectrometry Analysis of Bacterial Colonies Grown on Agar and in Tissue During Infection

Published on: November 18, 2022

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...